Home >Companies >News >Dr. Reddy’s launches epilepsy drug in the US market
Dr. Reddy’s lamotrigine tablets will be available in 25mg, 50mg, 100mg, 200mg, and 300mg dosages. (Dr. Reddy’s lamotrigine tablets will be available in 25mg, 50mg, 100mg, 200mg, and 300mg dosages.)
Dr. Reddy’s lamotrigine tablets will be available in 25mg, 50mg, 100mg, 200mg, and 300mg dosages.
(Dr. Reddy’s lamotrigine tablets will be available in 25mg, 50mg, 100mg, 200mg, and 300mg dosages.)

Dr. Reddy’s launches epilepsy drug in the US market

The firm launched lamotrigine extended-release tablets following approval by US Food and Drug Administration on 25 June

Drug maker Dr. Reddy’s Laboratories Ltd said on Wednesday it launched lamotrigine extended-release tablets in the US market following approval by the Food and Drug Administration on 25 June.

Lamotrigine is a generic version of GlaxoSmithKline Plc.’s lamictal XR used in the treatment of epilepsy.

According to US-based healthcare information service provider IMS Health, the lamictal XR brand and its generic had combined US sales of around $300.5 million for the 12 months ended April.

Dr. Reddy’s lamotrigine tablets will be available in 25mg, 50mg, 100mg, 200mg, and 300mg dosages.

Shares of Dr. Reddy’s dropped 0.32% to 2,093.15 on BSE, while the benchmark Sensex fell 0.41% to 18,552.12 points on Wednesday.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
My Reads Redeem a Gift Card Logout